相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FLT3-TKD in the prognosis of patients with acute myeloid leukemia: A meta-analysis
Shuping Li et al.
FRONTIERS IN ONCOLOGY (2023)
Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells
Xuejing Shao et al.
ACTA PHARMACEUTICA SINICA B (2022)
Aberrantly expressed Wnt5a in nurse-like cells drives resistance to Venetoclax in chronic lymphocytic leukemia
Yao Guo et al.
CELL DEATH DISCOVERY (2022)
The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia
Xiaomei Zhuang et al.
FRONTIERS IN ONCOLOGY (2022)
The Metabolic Signature of AML Cells Treated With Homoharringtonine
Yulong Zhang et al.
FRONTIERS IN ONCOLOGY (2022)
Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor
Dengyang Zhang et al.
BMC MEDICINE (2022)
Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression
Dengyang Zhang et al.
MICROBIAL CELL FACTORIES (2021)
Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations
Zhijie Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
Anne Sophie Kubasch et al.
LEUKEMIA (2020)
Tumor suppressor OTUD3 induces growth inhibition and apoptosis by directly deubiquitinating and stabilizing p53 in invasive breast carcinoma cells
Qian Pu et al.
BMC CANCER (2020)
Development of a highly sensitive method for detection of FLT3D835Y
Yao Guo et al.
BIOMARKER RESEARCH (2020)
Small RNA sequencing profiles of mir-181 and mir-221, the most relevant microRNAs in acute myeloid leukemia
Yun-Gyoo Lee et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2019)
Breaking the chains: deubiquitylating enzyme specificity begets function
Michael J. Clague et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 inhibits inflammation by regulating Nur77 stability
Han Zhong Pei et al.
CELLULAR SIGNALLING (2019)
Prognostic Role of miR-221 and miR-222 Expression in Cancer Patients: A Systematic Review and Meta-Analysis
Gloria Ravegnini et al.
CANCERS (2019)
Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia
Yun Chen et al.
BLOOD (2019)
Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia
Yasutaka Hayashi et al.
NATURE COMMUNICATIONS (2019)
p53 modifications: exquisite decorations of the powerful guardian
Yanqing Liu et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2019)
Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies
Jian Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery and characterization of highly potent and selective allosteric USP7 inhibitors
Gerald Gavory et al.
NATURE CHEMICAL BIOLOGY (2018)
MDM2-and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
Katja Seipel et al.
HAEMATOLOGICA (2018)
USP49 participates in the DNA damage response by forming a positive feedback loop with p53
Rongfu Tu et al.
CELL DEATH & DISEASE (2018)
MDM2-and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
Katja Seipel et al.
HAEMATOLOGICA (2018)
How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?
Brandon J. Aubrey et al.
CELL DEATH AND DIFFERENTIATION (2018)
p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status
A. Quintas-Cardama et al.
LEUKEMIA (2017)
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rajesha Rupaimoole et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges
Shaomeng Wang et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
p53 stability is regulated by diverse deubiquitinating enzymes
Seul-Ki Kwon et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2017)
USP3 stabilizes p53 protein through its deubiquitinase activity
Song Fu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts
Jared A. Wallace et al.
BLOOD (2017)
Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy
Miron Prokocimer et al.
BLOOD (2017)
Ovarian tumor domain-containing protein 1 deubiquitinates and stabilizes p53
Shudong Piao et al.
CELLULAR SIGNALLING (2017)
Identification of an orally available compound with potent and broad FLT3 inhibition activity
Y. Chen et al.
ONCOGENE (2016)
Pharmacological activation of wild-type p53 in the therapy of leukemia
Kensuke Kojima et al.
EXPERIMENTAL HEMATOLOGY (2016)
Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2
Zhuo Ren et al.
CELL DEATH & DISEASE (2016)
The tumour suppressor CYLD regulates the p53 DNA damage response
Vanesa Fernandez-Majada et al.
NATURE COMMUNICATIONS (2016)
The Machado-Joseph Disease Deubiquitinase Ataxin-3 Regulates the Stability and Apoptotic Function of p53
Hongmei Liu et al.
PLOS BIOLOGY (2016)
The impact of standard chemotherapy on miRNA signature in plasma in AML patients
Linda Koutova et al.
LEUKEMIA RESEARCH (2015)
Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML
Noah I. Hornick et al.
SCIENTIFIC REPORTS (2015)
The Deubiquitinating Enzyme USP24 Is a Regulator of the UV Damage Response
Ling Zhang et al.
CELL REPORTS (2015)
Monoubiquitination Is Critical for Ovarian Tumor Domain- containing Ubiquitin Aldehyde Binding Protein 1 ( Otub1) to Suppress UbcH5 Enzyme and Stabilize p53 Protein*
Yuhuang Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
USP11 regulates p53 stability by deubiquitinating p53
Jia-ying Ke et al.
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B (2014)
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo Kian Hoe et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation
Sharvan Sehrawat et al.
BLOOD (2013)
Overexpression of primary microRNA 221/222 in acute myeloid leukemia
Anna Rommer et al.
BMC CANCER (2013)
OTU Deubiquitinases Reveal Mechanisms of Linkage Specificity and Enable Ubiquitin Chain Restriction Analysis
Tycho E. T. Mevissen et al.
CELL (2013)
MicroRNAs Distinguish Cytogenetic Subgroups in Pediatric AML and Contribute to Complex Regulatory Networks in AML-Relevant Pathways
Svenja Daschkey et al.
PLOS ONE (2013)
OTUD5 Regulates p53 Stability by Deubiquitinating p53
Judong Luo et al.
PLOS ONE (2013)
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Mark Wade et al.
NATURE REVIEWS CANCER (2013)
The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status
Giorgio Zauli et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis
Wei-Chih Tsai et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells
Yao Guo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Deubiquitinases in cancer: new functions and therapeutic options
J. M. Fraile et al.
ONCOGENE (2012)
miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival
Jong-Kook Park et al.
CANCER RESEARCH (2011)
Regulation of p53 stability and function by the deubiquitinating enzyme USP42
Andreas K. Hock et al.
EMBO JOURNAL (2011)
Maintenance of genomic integrity in hematopoietic stem cells
Kazuhito Naka et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
M. H. Aziz et al.
ONCOGENE (2011)
USP10 Regulates p53 Localization and Stability by Deubiquitinating p53
Jian Yuan et al.
CELL (2010)
EPIGENETICS AND GENETICS Leukaemogenesis: more than mutant genes
Jianjun Chen et al.
NATURE REVIEWS CANCER (2010)
The emerging complexity of protein ubiquitination
David Komander
BIOCHEMICAL SOCIETY TRANSACTIONS (2009)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
Keith Wheatley et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation
Michela Garofalo et al.
CANCER CELL (2009)
The Otubain YOD1 Is a Deubiquitinating Enzyme that Associates with p97 to Facilitate Protein Dislocation from the ER
Robert Ernst et al.
MOLECULAR CELL (2009)
Diversity of degradation signals in the ubiquitin-proteasome system
Tommer Ravid et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Experimental validation of miRNA targets
Donald E. Kuhn et al.
METHODS (2008)
Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation
Carlos le Sage et al.
EMBO JOURNAL (2007)
p53 alterations in human cancer: more questions than answers
T. Soussi
ONCOGENE (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular recognition of p53 and MDM2 by USP7/HAUSP
Y Sheng et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2006)
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
K Kojima et al.
BLOOD (2005)
FLT3/ITD mutation signaling includes suppression of SHP-1
PL Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization
MY Li et al.
NATURE (2002)
分享论文
